Laboratoires d'excellence in Idex
Référence projet : 10-LABX-0015
RST : Guido KROEMER
Etablissement Coordinateur : COMUE Sorbonne Paris Cité
Région du projet : Île-de-France
Discipline : 5 - Bio Med
Aide de l'ANR 11 000 000 euros
Investissement couvrant la période de avril 2011 à décembre 2022
Throughout its existence (2011-2016), the LabEx “Immuno-Oncology” has operated along lines of astonishing excellence, as per its founding act. The 7 partners of the LabEx have produced top-standing scientific knowledge, as witnessed by some 813 articles that have been published in international, peer-reviewed scientific journals, including forums of the standing of Nature, Science, Cell, Nat Genet, Nat Med, Nat Immunol, Cell Metabol, Sci Transl Med, Immunity. In 2012, the LabEx has founded a new journal, “Oncoimmunology”, which has published a total of 2000 papers and in 2016 obtained its third impact factor of 7.64, confirming its status of the world-leading journal in the field. The LabEx has launched the European Academy of Tumor Immunology (EATI), a non-profit organization with the scope of creating a Europe-wide lobby in favor of excellence in tumor immunology research, fund raising at the EU and national levels, and clinical implementation of anticancer immunotherapies. In 2011-2016, the LabEx/EATI partnership organized or sponsored 14 international conferences in various locations, attracting an average of 500 participants from all over the world per meeting. Notably, the CRI-CIMT-EATI-AACR - Cancer Immunotherapy Conference held in New York in September 2015 and 2016 was attended by 1500 to 1700 participants. The LabEx also continues to promote seminars and courses devoted to the dissemination of scientific knowledge. Finally, the LabEx provides stable financial support to 3 centralized positions (1 Scientific Manager and 2 Biostatisticians) as well as 1 post-doctoral fellow per year per partner, and covers bench fees of PhD students and post-docs. Besides these objective and unquestionable achievements, the activities organized by the LabEx (like the innovative Trial Watch series published in OncoImmunology) earned highly enthusiastic feedback from the research community.
L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.